Kukje Pharma

KSC:002720 · KR7002720001

PharmaceuticalsSmall

360

Medium confidence — indicative

Value50

Profit price36

EV / EBIT60

Price / Owner Earnings12

Cash yield34

Owner Earnings Yield67

Dividend Yield1

Sales & asset price71

Price/Sales74

EV / Gross Profit82

Price/Book58

Quality60

Returns on capital80

Return on Capital82

Cash Return on Capital81

Return on Equity76

Profit margins83

EBIT Margin71

Gross Profitability95

Cash backing38

Cash Conversion19

Accruals24

Owner Earnings Margin71

Growth49

Sales growth49

Profit growth46

Profit Growth49

Long-Term EPS Growth25

Owner Earnings Growth65

Reinvestment40

Price momentum30

Safety38

Debt load46

Debt serviceability53

Refinancing68

Debt Payback38

Liquidity62

Sentiment45

Analyst ratings—

Expectations trend—

Market mood5

Value Creation8/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Kukje Pharma clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Employees3

Websitekukjepharm.co.kr

ISINKR7002720001

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

OphthalmologyOsteoporosisRespiratoryDiabetesCardiovascularCentral Nervous SystemCosmeticsHealth CareMedicalPharmaceutical

Description

Analysis

Middle-of-the-road

Kukje Pharma Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 12.3×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kukje Pharma with its peers

PharmGen Science

KSC:004720

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Samil Pharmaceutical

KSC:000520

CountrySouth Korea

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Korea United Pharm

KSC:033270

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Hana Pharm

KSC:293480

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Reyon Pharmaceutical

KSC:102460

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Samsung Pharm

KSC:001360

—

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →